IP Library Granted Patent US 8,278,418
Granted Patent B2
US 8,278,418 · App. 12/567,627 · Granted Oct 2, 2012

Modified animal erythropoietin polypeptides and their uses

Assignee: Ambrx, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,278,418
App. No.
12/567,627
Granted
Oct 2, 2012
Kind
B2
Abstract

Modified animal erythropoietin polypeptides and uses thereof are provide.

Claims (14)

1. A feline erythropoietin (fEPO) polypeptide comprising a non-naturally encoded amino acid substituted at position 1 of SEQ ID NO: 2,

wherein the non-naturally encoded amino acid is para-acetylphenylalanine, and

wherein the non-naturally encoded amino acid is linked to a water soluble polymer comprising a poly(ethylene) glycol moiety.

2. The fEPO polypeptide of claim 1 , wherein the water soluble polymer has a molecular weight of between about 0.1 kDa and about 100 kDa.

3. The fEPO polypeptide of claim 1 , wherein the water soluble polymer has a molecular weight of between about 0.1 kDa and about 50 kDa.

4. The fEPO polypeptide of claim 1 , wherein the water soluble polymer has a molecular weight of about 20 kDa.

5. The fEPO polypeptide of claim 1 , wherein the water soluble polymer has a molecular weight of about 30 kDa.

6. The fEPO polypeptide of claim 1 , wherein the water soluble polymer has a molecular weight of about 40 kDa.

7. A pharmaceutical formulation comprising the fEPO polypeptide of claim 1 and a pharmaceutically acceptable carrier.

8. The pharmaceutical formulation of claim 7 , wherein the water soluble polymer has a molecular weight of between about 0.1 kDa and about 100 kDa.

9. The pharmaceutical formulation of claim 7 , wherein the water soluble polymer has a molecular weight of between about 0.1 kDa and about 50 kDa.

10. The pharmaceutical formulation of claim 7 , wherein the water soluble polymer has a molecular weight of about 20 kDa.

11. The pharmaceutical formulation of claim 7 , wherein the water soluble polymer has a molecular weight of about 30 kDa.

12. The pharmaceutical formulation of claim 7 , wherein the water soluble polymer has a molecular weight of about 40 kDa.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2018
From: ELI LILLY AND COMPANY
To: ELANCO US INC.
Reel/Frame 044700/0566 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2010
From: TIAN, FENG; HAYS PUTNAM, ANNA-MARIA A.; SONG, FRANK; CHU, STEPHANIE; SHEFFER, JOSEPH; BARNETT, RICHARD S.; SILADI, MARC E.; ATKINSON, KYLE; LEE, DARIN
To: AMBRX, INC.
Reel/Frame 024446/0418 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2010
From: CANNING, PETER C.
To: ELI LILLY AND COMPANY
Reel/Frame 023756/0898 →
Continuity (3)
Provisional Application 61100679 · Sep 26, 2008
Provisional Application 61100692 · Sep 26, 2008
Related Publication 20100093608A1 · Apr 15, 2010